Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment

MT Newswires Live12-10

Novartis (NVS) said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in combination with endocrine therapy.

Latest data showed a sustained reduction in distant recurrence of 28.5% in patients versus endocrine therapy alone, the company said. Reduced distant recurrence - known as distant disease-free survival, or DDFS - refers to decreased rate of cancer returning and spreading to other organs, it said.

The DDFS with Kisqali was observed uniformly among all pre-specified patient subgroups, including those with node-negative disease, the company said.

Novartis said the late-breaking data presented at the 2024 San Antonio Breast Cancer Symposium also showed that Kisqali's safety profile remains unchanged, with no new safety signals having been identified.

Price: 100.79, Change: -0.89, Percent Change: -0.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490232017?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490232017","market":"hk","top_or_hot":-1,"title":"Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> Novartis (NVS) said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in combination with endocrine therapy.</p><p>Latest data showed a sustained reduction in distant recurrence of 28.5% in patients versus endocrine therapy alone, the company said. Reduced distant recurrence - known as distant disease-free survival, or DDFS - refers to decreased rate of cancer returning and spreading to other organs, it said.</p><p>The DDFS with Kisqali was observed uniformly among all pre-specified patient subgroups, including those with node-negative disease, the company said.</p><p>Novartis said the late-breaking data presented at the 2024 San Antonio Breast Cancer Symposium also showed that Kisqali's safety profile remains unchanged, with no new safety signals having been identified.</p><p>Price: 100.79, Change: -0.89, Percent Change: -0.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 23:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novartis (NVS) said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490232017","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490232017","pubTimestamp":1733846082,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novartis  said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in combination with endocrine therapy.Latest data showed a sustained reduction in distant recurrence of 28.5% in patients versus endocrine therapy alone, the company said. Reduced distant recurrence - known as distant disease-free survival, or DDFS - refers to decreased rate of cancer returning and spreading to other organs, it said.The DDFS with Kisqali was observed uniformly among all pre-specified patient subgroups, including those with node-negative disease, the company said.Novartis said the late-breaking data presented at the 2024 San Antonio Breast Cancer Symposium also showed that Kisqali's safety profile remains unchanged, with no new safety signals having been identified.Price: 100.79, Change: -0.89, Percent Change: -0.88","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4578":"CAR-T","BK4532":"文艺复兴科技持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","NVS":"诺华","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"诺华表示，长期数据凸显了Kisqali作为早期乳腺癌治疗的疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"Novartis (NVS) said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in combination with endocrine therapy.Latest data showed a sustained reduction in distant recurrence of 28.5% in patients versus endocrine therapy alone, the company said. Reduced distant recurrence - known as distant disease-free survival, or DDFS - refers to decreased rate of cancer returning and spreading to other organs, it said.The DDFS with Kisqali was observed uniformly among all pre-specified patient subgroups, including those with node-negative disease, the company said.Novartis said the late-breaking data presented at the 2024 San Antonio Breast Cancer Symposium also showed that Kisqali's safety profile remains unchanged, with no new safety signals having been identified.Price: 100.79, Change: -0.89, Percent Change: -0.88","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490232017"}